When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
Omeros' (OMER) business plan envisions that it use revenues from OMIDRIA, its FDA-approved therapy, to finance its exciting development pipeline. The company's plan has struggled over reimbursement issues in the past, which are likely to raise their head again.
This article discusses how Omeros is faring under the twin challenges of the current COVID-19 pandemic and possible disruption of its business plan.
After a tumultuous 2019, Omeros enjoyed a stellar run following its Q4 2019 earnings report
Time waits for no one. Take, for example, the following fragment of an article I was